Tofacitinib citrate utitur et mechanism agendi

2025-08-12

Tofacitinib citrate est innovative Janus Kinase (Jak) inhibitor quod habet reversed curatio de pluribus autoimmune conditionibus. Hoc comprehensive dux explorat orci applications, pharmacological mechanism, dosis formae et salus profileTofacitInib citrate, Providemus curis professionals cum essential notitia de hoc breakthrough medication developed aRun'an Pharmaceutical.

Tofacitinib Citrate

Volume applications of ToFacitInib citrate

TofacitInib citrateNumquid FDA-probatus pro multiple therapeutica indicia cum probata efficacia in:

I. Rheumatoid Arthritis (RA)

    Moderare gravibus active ra in adultis

    MethotRexate combination et Monotherapy

    Reduces iuncturam tumor et progressionem structural damnum

II. PSoriatic (Psa)

    Active Psa in aegris cum sufficiens responsum ad DCards

    Amplio enthesitis et dactylitis

III. Ulcative Colitis (UC)

    Moderare gravibus active UC

    Inductionem et sustentationem remissionis

IV. Alii investigans usus

    Ankylosing spondylitis

    ALPECIA Areata

    Iuvenalibus idiopathic arthritis

Indicium Dosage forma Commendatur dose Curatio
Rheumatoid arthritis Tablet (5mg) 5mg bis cotidie Longinquus
Psoriatic arthritis Tablet (5mg) 5mg bis cotidie Longinquus
Ulcerative colitis Fundo, release (11mg) 11Mg cum cotidie Inductio: VIII weeks

Pharmacological mechanism agendi

TofacitInib citrateExerit eius medicinales effectus per:

Jak-Stat Semita inhibitionis

    Electionem inhibitionis de Jak1 et Jak3

    Modulation de Cytokine Signaling (II-II, II-IV, I-VII, IL IX, II-XV, II-XXI)

    Reductionem de inflammatione mediatores

Immunomodulatory effectus

    Minuitur circulating CD16 + / CD56 + NK cellulis

    Reduces Serum C, Reactive dapibus (CRP) campester

    Moderator matrix metalloproteinase (MMMP) campester

Cellular impulsum
Cellula type Ecfectio Volume exitus
T cellulis Reducitur proliferation Ibant inflammatio
B cellulis Limitata activation Inferius Autoantibody productio
Macrophages Inhibuit activation Reducitur TEXTUS damnum

Salus profile et periculo procuratio

Commune adversa effectus

    Superioris respiratorii tractu infectiones (15-20%)

    Capitis (4-7%)

    Fluxus (3-5%)

    Auctus LDL Cholesterol (10-15%)

Grave metus

✔ Herpesvirus Zosti Reactivation
✔ thromboembolic certe
✔ lymphoma et aliis malignancies
✔ gastrointestinal perforationes

Quid eligere Run'an Pharmaceutical Tofacitinib citrate?

✔ CGMP, certified facilities facilities
✔ stricte qualis imperium valde pharmacopeial signa
✔ comprehensive stabilitatem studiis
✔ Global regulatory obsequio (FDA, Ema, PMDA)
✔ Competitive Morbi cursus sapien pro curis systems

Nam productum notitia, orci notitia, aut societate occasiones:

Sicut dux scientific ad curru'an pharmaceutical cum XX annos experientia in immunomodulatory therapies, ego personaliter praestare qualis et efficaciam nostrorumTofacitInib citrateformulae. Contact nostri Medical Negotiis Team hodie ut de quid possumus sustinere vestri medicinales necessitates.

    No. XII, Zhangma Road, sal chemical novum materiae industriae parcum
    Wangjing@ctqjph.com
    + 86-13646196320
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept